Lunit's Summit deal lifts Korean medical AI stocks[K-Bio Pulse]
Predicted impact: Medium
Summit AI collaboration already reported in last 14 days; sector-wide stock move, no deal size given.
Lunit루닛
328130 · KOSDAQ · ₩328130 · 루닛
₩15,690▲ ₩710 (4.74%)End-of-day · Oct 30, 2026 · End-of-day prices.
Price · 1Y −16.74%
- Market cap
- ₩1.2T
- Enterprise value
- ₩1.1T
- P/E
- —
- P/B
- 3.5×
- Dividend yield
- 0.0%
- ROE
- −16.8%
- Net margin
- −60.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−36.1% from the high
₩8,180Today: ₩14,610 – ₩16,150₩24,550
Returns
- 1W+38.8%
- 1M+44.1%
- 3M+69.6%
- 6M−24.4%
- YTD−18.6%
- 1Y−16.7%
- Volume today
- 4,108,233
- 2.6× the 20-day average
- Traded today
- ₩64B
- Listed shares
- 74,458,180
- EPS (12 months)
- −₩748
- Earnings yield −4.8%
AI research · Update noteLunit Shares Rise 15.7% in Five Days on Heavy Volume After Summit Collaboration NewsThe evidence is mixed.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+4.7% on Oct 30, 2026. Trading value 3.1× its normal.
Lunit, a Korean medical AI company, is in the news after a deal with Summit lifted Korean medical AI stocks. The source gives no further detail on the deal's size or terms.
AI summary of the news and filings linked. It can be wrong; check them.
- • Foreign investors sold a net ₩1.2B that day
- • Buzz 67 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Warming up- BuzzRisingBuzz 67: heavy trading.
- SentimentPositiveNews: Headline says the Summit deal lifted the stock group, which reads as mildly positive. Community: 0 bullish, 0 bearish posts this week.
- MomentumStrong33% over the last month; the price is above its 20-day average.
- News impactSome3 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 30: sell ₩892M at the close (4.0% of 20-day average trading value)
On its 29 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 15.2% of trading value and pointed the same way 18 of 29 times.
- 2× KODEX KOSDAQ150 Leverage −₩769M
- -1× KODEX KOSDAQ150 Futures Inverse −₩53M
- 2× TIGER KOSDAQ150 Leverage −₩49M
- 2× RISE KOSDAQ150 Futures Leverage −₩14M
- -1× TIGER KOSDAQ150 Futures Inverse −₩2.7M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- ACE KOSDAQ 1500.5%
- HANARO KOSDAQ1500.5%
- IBK KOSDAQ1500.5%
- KIWOOM KOSDAQ1500.5%
- KODEX KOSDAQ1500.5%
- KODEX KOSDAQ150 Leverage2×0.5%
- PLUS KOSDAQ1500.5%
- RISE KOSDAQ1500.5%
Estimated from the funds' index or underlying stock.
Lunit stock overview
Lunit (루닛, KRX: 328130) is listed on KOSDAQ, in the Software sector. Lunit is a Korean deep-learning medical AI company founded in 2013 that focuses on medical imaging, particularly cancer diagnosis. Its shares closed at ₩15,690 on Oct 30, 2026, up 4.74% on the day, giving it a market value of ₩1.2T.
Key facts
- Market cap
- ₩1.2T
- Sector
- Software
- Latest price change
- +4.74%
- As of
- Oct 30, 2026
- Main business
- Lunit is a Korean deep-learning medical AI company founded in 2013 that focuses on medical imaging, particularly cancer diagnosis.
Quick answers about Lunit
- What does Lunit do?
- Lunit is a Korean deep-learning medical AI company founded in 2013 that focuses on medical imaging, particularly cancer diagnosis. Its main products include Lunit INSIGHT, which assists radiologists in detecting abnormalities in chest X-rays, mammography and digital breast tomosynthesis images, and Lunit SCOPE, which quantifies biomarkers from digital pathology slides and predicts immunotherapy response for oncology research and drug development. Its customers include medical institutions and global partners such as GE Healthcare, Philips, Fujifilm and Hologic, as well as pharmaceutical companies, with sales mostly outside Korea and operations in the United States, Japan, Australia and Canada.
- What is the market cap of Lunit?
- The market capitalisation of Lunit was ₩1.2T at the close on Oct 30, 2026.
- Who are the largest shareholders of Lunit?
- According to the latest official filings, the largest reported holders are Baek Seung-wook (8.80%, as of Jun 30, 2026); Samsung Asset Management (4.12%, as of May 7, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (3.17%, as of Jul 31, 2026).
- When is the next earnings report from Lunit?
- Korean companies rarely announce results dates in advance. Based on when Lunit filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
- Does the National Pension Service own Lunit?
- Yes. The National Pension Service held 1.21% of Lunit shares as of Dec 31, 2025.
Company profile
Lunit is a Korean deep-learning medical AI company founded in 2013 that focuses on medical imaging, particularly cancer diagnosis. Its main products include Lunit INSIGHT, which assists radiologists in detecting abnormalities in chest X-rays, mammography and digital breast tomosynthesis images, and Lunit SCOPE, which quantifies biomarkers from digital pathology slides and predicts immunotherapy response for oncology research and drug development. Its customers include medical institutions and global partners such as GE Healthcare, Philips, Fujifilm and Hologic, as well as pharmaceutical companies, with sales mostly outside Korea and operations in the United States, Japan, Australia and Canada.
Written by AI from the company's latest annual report.
- Korean name
- 루닛
- Sector
- Software
- CEO
- 서범석
- Founded
- Aug 2013
- Listed
- Jul 2022
- Listed shares
- 74,458,180
- Fiscal year ends
- Month 12
- Website
- www.lunit.io
Similar companies
- Krafton259960 · ₩8.4T₩182,100+0.61%
- Hyundai Autoever307950 · ₩7.9T₩289,000−13.08%
- NC036570 · ₩4.3T₩201,500+1.00%
- Netmarble251270 · ₩2.8T₩33,7500.00%
- PearlAbyss263750 · ₩2.2T₩35,000+1.45%
- Shift UP462870 · ₩1.7T₩29,450−0.51%
- NHN181710 · ₩1.5T₩46,600−2.71%
- Ahnlab053800 · ₩1.3T₩118,100+17.98%
Recent news
Lunit jumps 26% on KOSDAQ after collaboration with US company
Predicted impact: Low
Collaboration with a US firm; no contract value given, only a share price jump.
Lunit Analyzes Ibonecimab with Summit Using AI
Predicted impact: Low
AI analysis collaboration with no contract value or financial size given.
Recent filings
See all- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturityOct 2, 2026
- Adjustment of Conversion PriceOct 1, 2026
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturitySep 28, 2026
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturitySep 23, 2026
- Adjustment of Conversion PriceSep 4, 2026
Titles in Korean until English translations are added.
Also known as: Lunit / 루닛 / 328130 / KRX:328130
Source: KRX statistical information